glp-1 with hypothyroidism and Does anyone with hypothyroidism take

Ozempic and similar semaglutide drugs might be associated with medical conditions such as gastroparesis (stomach paralysis), gallbladder disease, cyclic vomiting syndrome, and other serious conditions

The American Diabetes Association Standards of Care emphasize the importance of monitoring for adverse effects and adjusting treatment as needed to optimize tolerability while maintaining therapeutic benefit

Several factors influence the patients level of adherence and can be distinguished as social and economic factors, patient-related factors (health beliefs, health literacy), therapy-related factors (complexity of the treatment, adverse events), presence of comorbidities (neurological/psychiatric or of different origins), and factors related to the healthcare system (doctor-patient relationship, difficulty in obtaining follow-up visits)

Elevated levels of serum glutamic pyruvic transaminase (SGPT, also as known as ALT), serum glutamic oxaloacetic transaminase (SGOT, also known as AST), urine albumin, and albumin/creatinine ratio were also noted, indicating potentially poorer kidney and liver function

Cohen discussed the potential benefits of GLP-1 as a tool to assist with weight loss

Gastrointestinal side effects are the most commonly reported and include: Nausea (affecting 1040% of patients, depending on the specific GLP-1 agonist) Vomiting and diarrhoea (less common than nausea but can contribute to dehydration) Constipation (due to slowed gastric emptying) Abdominal discomfort or bloating These effects are typically most pronounced during treatment initiation and following dose increases